Clinical TrialApr 16, 2026, 07:26 AM
Alterity's ATH434 Shows Disease-Modifying Signal in MSA at AAN Meeting
AI Summary
Alterity Therapeutics announced that its Chief Medical Advisor, Dr. Daniel Claassen, will deliver an oral presentation at the American Academy of Neurology (AAN) Annual Meeting. The presentation will highlight that ATH434 demonstrated a disease-modifying signal in Multiple System Atrophy (MSA) using the MuSyCA Composite Scale. This positive data follows previous reports of clinically meaningful efficacy in Phase 2 trials, positioning the company to initiate a Phase 3 pivotal trial for MSA.
Key Highlights
- Dr. Daniel Claassen to present ATH434 data at AAN Annual Meeting.
- Oral presentation on April 21, 2026, at 6:21 PM CT.
- ATH434 showed disease-modifying signal in Multiple System Atrophy.
- Data from Phase 2 clinical trial using MuSyCA Composite Scale.
- Company preparing to initiate Phase 3 pivotal trial in MSA.